<?xml version="1.0" encoding="UTF-8"?>
<p class="p">In view of the development of new anti-HIV therapy targeting the single steps of HIV life cycle, thousands of molecules have been tested. Among these, many have been designed and screened as virus entry inhibitors. [
 <xref rid="pone.0204042.ref006" ref-type="bibr" class="xref">6</xref>, 
 <xref rid="pone.0204042.ref007" ref-type="bibr" class="xref">7</xref>] Nowadays, enfuvirtide is the only effective entry inhibitor approved for use as anti-HIV in humans. [
 <xref rid="pone.0204042.ref008" ref-type="bibr" class="xref">8</xref>–
 <xref rid="pone.0204042.ref010" ref-type="bibr" class="xref">10</xref>] It is used in combined therapy with other anti-HIV drugs, but owing to its peptide nature—responsible for poor pharmacokinetic and high economic cost-, it has a restricted clinical application.
</p>
